0QAV.L
Nanobiotix S.A. [0QAV.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0QAV.L Stock Summary
Top 10 Correlated Stocks
0QAV.L
In the News
0QAV.L Financial details
Company Rating
Sell
Market Cap
255.67M
Income
-101.72M
Revenue
9.4M
Book val./share
-1.54
Cash/share
0.62
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
04 Sep 2024
P/E
-4.13
Forward P/E
-
PEG
-0.36
P/S
50.13
P/B
-4.51
P/C
8.33
P/FCF
-9.08
Quick Ratio
0.46
Current Ratio
0.67
Debt / Equity
-0.74
LT Debt / Equity
-0.74
-
-
EPS (TTM)
-2.92
EPS next Y
-
EPS next Q
-
EPS this Y
21.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.14%
Revenue last 5Y
6.54%
Revenue Q/Q
-4.47%
EPS Q/Q
-9.09%
-
-
-
-
SMA20
-16.67%
SMA50
-28.57%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-145%
ROE
145%
ROC
4.89%
Gross Margin
100%
Oper. Margin
-685%
Profit Margin
-872%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.624-10.38
52W High
-48.34%
52W Low
+416.61%
RSI
30
Rel Volume
1
Avg Volume
8.59K
Volume
8.63K
Perf Week
-9.05%
Perf Month
-12.44%
Perf Quarter
-11.39%
Perf Half Y
-17.87%
-
-
-
-
Beta
1.252
-
-
Volatility
0.19%, 0.19%
Prev Close
-2.16%
Price
5.16611
Change
-4.33%
0QAV.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.18 | 0 | 0 | 0 | 0.14 | |
| Net income per share | -1.55 | -2.35 | -1.38 | -1.35 | -1.64 | |
| Operating cash flow per share | -1.32 | -1.92 | -1.16 | -0.89 | -1.09 | |
| Free cash flow per share | -1.35 | -1.99 | -1.16 | -0.9 | -1.09 | |
| Cash per share | 1.85 | 1.62 | 4.89 | 2.42 | 1.19 | |
| Book value per share | 0.73 | -0.09 | 2.89 | 0.77 | -0.78 | |
| Tangible book value per share | 0.72 | -0.1 | 2.88 | 0.77 | -0.78 | |
| Share holders equity per share | 0.73 | -0.09 | 2.89 | 0.77 | -0.78 | |
| Interest debt per share | 1.09 | 2.01 | 2.01 | 1.19 | 1.56 | |
| Market cap | 219.35M | 241.84M | 272.63M | 253.73M | 126.16M | |
| Enterprise value | 203.67M | 251.27M | 202.46M | 215.83M | 140.76M | |
| P/E ratio | -7.23 | -4.75 | -8.12 | -5.4 | -2.21 | |
| Price to sales ratio | 63.05 | 3.56K | 5.45K | 25.37K | 26.42 | |
| POCF ratio | -8.44 | -5.82 | -9.65 | -8.18 | -3.32 | |
| PFCF ratio | -8.31 | -5.63 | -9.62 | -8.12 | -3.31 | |
| P/B Ratio | 15.4 | -118.61 | 3.87 | 9.51 | -4.66 | |
| PTB ratio | 15.4 | -118.61 | 3.87 | 9.51 | -4.66 | |
| EV to sales | 58.54 | 3.7K | 4.05K | 21.58K | 29.47 | |
| Enterprise value over EBITDA | -6.92 | -5.3 | -5.45 | -4.47 | -2.87 | |
| EV to operating cash flow | -7.84 | -6.05 | -7.17 | -6.96 | -3.7 | |
| EV to free cash flow | -7.71 | -5.85 | -7.14 | -6.91 | -3.69 | |
| Earnings yield | -0.14 | -0.21 | -0.12 | -0.19 | -0.45 | |
| Free cash flow yield | -0.12 | -0.18 | -0.1 | -0.12 | -0.3 | |
| Debt to equity | 1.44 | -18.99 | 0.63 | 1.52 | -1.8 | |
| Debt to assets | 0.44 | 0.69 | 0.33 | 0.4 | 0.81 | |
| Net debt to EBITDA | 0.53 | -0.2 | 1.89 | 0.79 | -0.3 | |
| Current ratio | 3.68 | 3.22 | 6.58 | 2.53 | 1.38 | |
| Interest coverage | -35.5 | -10.26 | -7.76 | -74.22 | -8.65 | |
| Income quality | 0.86 | 0.82 | 0.84 | 0.66 | 0.67 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 6.01 | 423.56 | 458.56 | 2.92K | 6.59 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.03 | 0 | 0.01 | 0 | |
| Capex to revenue | -0.12 | -21.24 | -2.14 | -23.3 | -0.02 | |
| Capex to depreciation | -0.67 | -0.82 | -0.06 | -0.15 | -0.06 | |
| Stock based compensation to revenue | 0.54 | 63.53 | 58.48 | 320.1 | 0.66 | |
| Graham number | 5.03 | 2.23 | 9.46 | 4.84 | 5.35 | |
| ROIC | -0.77 | -1.1 | -0.31 | -0.65 | -1.8 | |
| Return on tangible assets | -0.66 | -0.91 | -0.25 | -0.46 | -0.95 | |
| Graham Net | 0.22 | -0.77 | 2.4 | 0.34 | -1.19 | |
| Working capital | 31.05M | 31.78M | 106.21M | 56.22M | 14.42M | |
| Tangible asset value | 14.14M | -2.2M | 70.34M | 26.69M | -27.05M | |
| Net current asset value | 10.7M | -11.99M | 61.69M | 18.08M | -34.46M | |
| Invested capital | 1.44 | -18.99 | 0.63 | 1.52 | -1.8 | |
| Average receivables | 97K | 4.19M | 6.12M | 3.88M | 4.64M | |
| Average payables | 3.94M | 6.15M | 7.44M | 6.05M | 4.5M | |
| Average inventory | 0.5 | 0 | 0 | 0 | 50K | |
| Days sales outstanding | 2.62 | 44.88K | 28.32K | 141.73K | 411.77 | |
| Days payables outstanding | 0 | -1.15K | -1.14K | -691.52 | 973.09 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 24.33 | |
| Receivables turnover | 139.16 | 0.01 | 0.01 | 0 | 0.89 | |
| Payables turnover | 0 | -0.32 | -0.32 | -0.53 | 0.38 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 15 | |
| ROE | -2.13 | 24.97 | -0.48 | -1.76 | 2.11 | |
| Capex per share | -0.02 | -0.07 | 0 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.04 | 0.04 | 0.1 | 0.09 | |
| Net income per share | -0.88 | -0.48 | -0.76 | -0.88 | -0.8 | |
| Operating cash flow per share | -0.45 | -0.45 | -0.51 | -0.58 | -0.49 | |
| Free cash flow per share | -0.45 | -0.45 | -0.52 | -0.58 | -0.5 | |
| Cash per share | 2.96 | 2.41 | 1.81 | 1.19 | 0.62 | |
| Book value per share | 1.2 | 0.77 | 0.05 | -0.78 | -1.54 | |
| Tangible book value per share | 1.2 | 0.77 | 0.05 | -0.78 | -1.54 | |
| Share holders equity per share | 1.2 | 0.77 | 0.05 | -0.78 | -1.54 | |
| Interest debt per share | 1.42 | 1.17 | 1.23 | 1.48 | 1.14 | |
| Market cap | 386.47M | 254.29M | 116.04M | 126.17M | 165.38M | |
| Enterprise value | 334.85M | 216.39M | 98.13M | 140.76M | 143.75M | |
| P/E ratio | -3.18 | -3.83 | -1.1 | -1.03 | -1.47 | |
| Price to sales ratio | 38.65K | 191.48 | 87.32 | 36.6 | 50.22 | |
| POCF ratio | -25.06 | -16.32 | -6.49 | -6.26 | -9.57 | |
| PFCF ratio | -24.98 | -16.13 | -6.46 | -6.26 | -9.4 | |
| P/B Ratio | 9.35 | 9.53 | 67.04 | -4.67 | -3.07 | |
| PTB ratio | 9.35 | 9.53 | 67.04 | -4.67 | -3.07 | |
| EV to sales | 33.49K | 162.94 | 73.84 | 40.84 | 43.65 | |
| Enterprise value over EBITDA | -13.46 | -9.26 | -3.85 | -5.99 | -5.73 | |
| EV to operating cash flow | -21.71 | -13.89 | -5.49 | -6.99 | -8.32 | |
| EV to free cash flow | -21.64 | -13.73 | -5.46 | -6.98 | -8.17 | |
| Earnings yield | -0.08 | -0.07 | -0.23 | -0.24 | -0.17 | |
| Free cash flow yield | -0.04 | -0.06 | -0.15 | -0.16 | -0.11 | |
| Debt to equity | 1.11 | 1.52 | 23.25 | -1.8 | -0.74 | |
| Debt to assets | 0.37 | 0.4 | 0.5 | 0.81 | 0.99 | |
| Net debt to EBITDA | 2.08 | 1.62 | 0.7 | -0.62 | 0.86 | |
| Current ratio | 3.05 | 2.53 | 1.71 | 1.38 | 0.67 | |
| Interest coverage | -8.25 | 0 | -9.64 | -7.79 | 0 | |
| Income quality | 0.51 | 0.94 | 0.68 | 0.66 | 0.61 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.49K | 10.81 | 11.99 | 4.51 | 5.41 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0.02 | |
| Capex to revenue | -5 | -0.14 | -0.06 | 0 | -0.1 | |
| Capex to depreciation | -0.06 | -0.24 | -0.11 | -0.02 | -0.44 | |
| Stock based compensation to revenue | 139.8 | 1.36 | 1.02 | 0.53 | 0.41 | |
| Graham number | 4.87 | 2.87 | 0.92 | 3.92 | 5.26 | |
| ROIC | -0.27 | -0.31 | -0.54 | -0.84 | 1.83 | |
| Return on tangible assets | -0.25 | -0.16 | -0.33 | -0.51 | -0.7 | |
| Graham Net | 0.71 | 0.34 | -0.27 | -1.19 | -2.05 | |
| Working capital | 77.83M | 56.22M | 30.28M | 14.42M | -16.23M | |
| Tangible asset value | 41.33M | 26.69M | 1.73M | -27.05M | -53.78M | |
| Net current asset value | 33.39M | 18.08M | -5.97M | -34.46M | -60.56M | |
| Invested capital | 1.11 | 1.52 | 23.25 | -1.8 | -0.74 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 56.59K | 263.16 | 569.8 | 140.68 | 29.79 | |
| Days payables outstanding | -497.85 | 592.41 | 665.95 | 477.33 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 11.94 | 0 | |
| Receivables turnover | 0 | 0.34 | 0.16 | 0.64 | 3.02 | |
| Payables turnover | -0.18 | 0.15 | 0.14 | 0.19 | 0 | |
| Inventory turnover | 0 | 0 | 746K | 7.54 | 0 | |
| ROE | -0.74 | -0.62 | -15.23 | 1.13 | 0.52 | |
| Capex per share | 0 | -0.01 | 0 | 0 | -0.01 |
0QAV.L Frequently Asked Questions
What is Nanobiotix S.A. stock symbol ?
Nanobiotix S.A. is a FR stock and trading under the symbol 0QAV.L
What is Nanobiotix S.A. stock quote today ?
Nanobiotix S.A. stock price is $5.16611 today.
Is Nanobiotix S.A. stock public?
Yes, Nanobiotix S.A. is a publicly traded company.
Company Profile
- Volume Average 8.59K
- Market Capitalization 255.67M
- Employee 101
- CEO Mr. Laurent Levy Ph.D.
- Headquarters Paris,FR
- IPO Date 2014-02-13
-
Website
https://www.nanobiotix.com 
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
